Recently, the 139th session of the China Import and Export Fair, commonly known as the Canton Fair, took place in Guangzhou. During this prestigious event, Taiji, a renowned Chinese national medicine enterprise, made a notable appearance by showcasing its core biopharmaceutical drug, semaglutide, which is currently under research. This move not only highlighted Taiji's innovative prowess but also served as a catalyst for attracting global investment.

To date, Taiji has established state-of-the-art production facilities for both active pharmaceutical ingredients (APIs) and formulations, adhering to the stringent Good Manufacturing Practice (GMP) standards set by both China and the United States. Moreover, the raw materials used in their product have successfully completed the Drug Master File (DMF) filing process with the U.S. Food and Drug Administration (FDA), underscoring Taiji's capability to supply products on a global scale.